Effects of Proton Pump Inhibitor for Laryngopharyngeal Reflux and Comorbid Chronic Rhinosinusitis / 대한이비인후과학회지
Korean Journal of Otolaryngology - Head and Neck Surgery
; : 165-170, 2019.
Article
in Ko
| WPRIM
| ID: wpr-830056
Responsible library:
WPRO
ABSTRACT
BACKGROUND AND OBJECTIVES@#Laryngopharyngeal reflux (LPR) is a prevalent condition with an increasing incidence, and several recent studies have reported the association of LPR with chronic rhinosinusitis (CRS). In this study, we studied the effect of proton-pump inhibitors (PPIs) on symptom improvement for LPR and comorbid CRS.SUBJECTS AND METHOD:
Enrolled in the study from January 2017 to December 2017 were 164 patients (54 male, 110 female, mean age 48.8 years) who were diagnosed as LPR by reflux symptom index (RSI) or reflux finding scores (RFS) and comorbid CRS. Sino-Nasal Outcome Test (SNOT)-20 and Lund-Kennedy endoscopic scores were evaluated for CRS severity. The study group was divided into PPI treatment group (Ilaprazole 20 mg, once a day for 8 weeks) and non-treatment group. The RSI, RFS, SNOT-20, and Lund-Kennedy endoscopic scores were repeated at the end of treatment.@*RESULTS@#Ninety-two patients were prescribed PPI and 72 patients were not. Initial RSI, RFS, SNOT-20, and Lund-Kennedy score did not differ between the two groups. RSI and RFS decreased significantly after eight weeks of PPI medication (p=0.002 and p<0.001, respectively). In the non-treatment group, only RFS showed statistically significant decrease. SNOT-20 and Lund-Kennedy endoscopic scores decreased significantly in the treatment group (p=0.005 and p<0.001, respectively) compared to the non-treatment group.@*CONCLUSION@#The results of our study suggest that PPI treatment for 8 weeks was effective in reducing signs and symptoms of both LPR and CRS.
Full text:
1
Database:
WPRIM
Language:
Ko
Journal:
Korean Journal of Otolaryngology - Head and Neck Surgery
Year:
2019
Document type:
Article